Relapse and disability outcomes in patients with MS

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Relapse and disability outcomes in patients with MS

Postby MSUK » Mon Apr 09, 2012 11:51 pm

Relapse and disability outcomes in patients with MS treated with fingolimod

Image

Subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

Summary

Background
Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2212
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service